Search results
Showing 46 to 60 of 111 results for thyroid
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.
View quality statements for QS28Show all sections
Sections for QS28
- Quality statements
- Quality statement 1: Diagnosis – ambulatory blood pressure monitoring
- Quality statement 2: Investigations for target organ damage
- Quality statement 3: Statin therapy
- Quality statement 4: Blood pressure targets
- Quality statement 5: Review of cardiovascular disease risk factors
- Quality statement 6: Referral to a specialist for adults with resistant hypertension
- Update information
recommendationsThyroid hormone replacementThe committee agreed that hypothyroidism needs thyroid hormone replacement. Potential...
Minimally invasive video‑assisted parathyroidectomy (HTG350)
Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.
subclinical hyperthyroidism is persistent and appears to be caused by intrinsic thyroid disease. However, the committee noted that there...
Selumetinib for treating differentiated thyroid cancer [ID1079]
Discontinued Reference number: GID-TA10207
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
reduction in surgical interventions. Capacity savings: £5,100 Guideline on thyroid disease: assessment and management (NG145) Savings...
long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...
long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...
long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...
Implantation of an opaque intraocular lens for intractable double vision (HTG185)
Evidence-based recommendations on implantation of an opaque intraocular lens for intractable double vision. This involves replacing the clear lens of one eye with a non-transparent one to block out one of the double images.
View recommendations for HTG185Show all sections
Sections for HTG185
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
Discontinued Reference number: GID-TA11259